Generation of stable suspension producer cell lines for serum‐free lentivirus production

Abstract The production of lentiviral vectors (LVs) pseudotyped with the vesicular stomatitis virus envelope glycoprotein (VSV‐G) is limited by the associated cytotoxicity of the envelope and by the production methods used, such as transient transfection of adherent cell lines. In this study, we established stable suspension producer cell lines for scalable and serum‐free LV production derived from two stable, inducible packaging cell lines, named GPRG and GPRTG. The established polyclonal producer cell lines produce self‐inactivating (SIN) LVs carrying a WAS‐T2A‐GFP construct at an average infectious titer of up to 4.64 × 10 7 TU mL −1 in a semi‐perfusion process in a shake flask and can be generated in less than two months. The derived monoclonal cell lines are functionally stable in continuous culture and produce an average infectious titer of up to 9.38 × 10 7 TU mL −1 in a semi‐perfusion shake flask process. The producer clones are able to maintain a productivity of >1 × 10 7 TU mL −1 day −1 for up to 29 consecutive days in a non‐optimized 5 L stirred‐tank bioreactor perfusion process, representing a major milestone in the field of LV manufacturing. As the producer cell lines are based on an inducible Tet‐off expression system, the established process allows LV production in the absence of inducers such as antibiotics. The purified LVs efficiently transduce human CD34 + cells, reducing the LV quantities required for gene and cell therapy applications.